Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages

Protagonist Therapeutics’ drug rusfertide reduced the need for phlebotomies as a way to treat the rare blood cancer polycythemia vera. Longer-term Phase 3 data for the Takeda Pharmaceutical-partnered peptide drug were presented during the annual meeting of the American Society of Hematology. The post Shining Light on How Protagonist, Takeda Drug Brings Treatment of a…

Read More

The rise in fabricated citations

From a Topaz et al. (2026) paper in The Lancet reviewing citations across 2.5 peer-reviewed papers in PubMed: Among 97·1 million verified references, we identified 4046 fabricated references across 2810 papers (illustrative examples are shown in the appendix p 5–6). In 2023, approximately one in 2828 papers contained at least one fabricated reference. By 2025,…

Read More